IGF-1 LR3

About IGF-1 LR3

IGF-1 LR3 (Long Arg³ Insulin-like Growth Factor-1) is a synthetic 83-amino-acid peptide that's been engineered to work better than the natural IGF-1 your body produces. This lab-made peptide has two key modifications: an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminal end. These changes make a big difference. They drastically reduce how much the peptide binds to IGF binding proteins, whilst extending its active half-life from just minutes to several hours. That's a game-changer for research applications. Studies have shown IGF-1 LR3 packs serious anabolic punch in cellular research. It's particularly good at ramping up protein synthesis and getting cells to multiply through the PI3K/Akt signalling pathway. Researchers have been exploring its potential in muscle tissue studies, wound healing research, and cellular regeneration work. Here's what's impressive: studies suggest IGF-1 LR3 is roughly 2.5 times more potent than natural IGF-1 when it comes to promoting myoblast proliferation. That's substantial. Our pharmaceutical-grade IGF-1 LR3 comes as a freeze-dried powder with over 98% purity—verified through HPLC analysis. We manufacture it under strict GMP conditions to ensure you get consistent results every time. Each vial contains precisely specified molecular weight suitable for advanced biotechnology research protocols. For in vitro laboratory research use only.

Research Applications

• Studied for its role in IGF-1 receptor binding with reduced affinity to IGFBP-3 relative to native IGF-1.
• Investigated for association with myoblast proliferation and differentiation pathways in cell culture.
• Researched for involvement in PI3K/Akt and MAPK downstream signalling cascades in vitro.
• Examined for its role in extended bioactive half-life profiles in preclinical pharmacokinetic models.

Research Mechanism — IGF-1 LR3

A simplified summary of what IGF-1 LR3 is studied for in research models. For laboratory in-vitro use only.

1. 1

   Molecular target

   IGF-1 LR3 is studied as a high-affinity ligand of the type 1 IGF receptor. The Arg³ substitution is associated with reduced IGFBP-3 sequestration in vitro.

   • Type 1 IGF receptor (IGF-1R) tyrosine kinase
   • Reduced affinity for IGFBP-1 through IGFBP-6
   • Cross-reactivity with the insulin receptor (IR)
2. 2

   Investigated pathways

   Research has examined receptor autophosphorylation and recruitment of IRS-1/IRS-2 adaptors. Downstream signalling cascades have been characterised in cultured myoblasts and fibroblasts.

   • PI3K/AKT/mTOR axis activation
   • Ras/Raf/MEK/ERK1/2 mitogenic cascade
   • FoxO transcription factor phosphorylation
3. 3

   Preclinical research applications

   Preclinical studies have explored IGF-1 LR3 in cell-culture proliferation assays and rodent skeletal muscle models. Not approved for human use.

   • C2C12 myoblast differentiation assays
   • Rodent satellite cell proliferation studies
   • In vitro models of IGF-1R signalling kinetics

For research use only. IGF-1 LR3 is not approved as a medicine in the UK and is not intended for human or veterinary administration. See the compliance page for full terms.